| Mitchell L Bressack, MD | |
|
70 W 94th Place, Crown Point, IN 46307-1710 | |
| (219) 662-8822 | |
| (219) 662-8833 |
| Full Name | Mitchell L Bressack |
|---|---|
| Gender | Male |
| Speciality | Dermatology |
| Experience | 46 Years |
| Location | 70 W 94th Place, Crown Point, Indiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1346245115 | NPI | - | NPPES |
| 100214910A | Medicaid | IN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | 036059363 (Illinois) | Secondary |
| 207N00000X | Dermatology | 01031629 (Indiana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Rush University Medical Center | Chicago, IL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Rush University Medical Center | 5496658874 | 1007 |
News Archive
In an article published today in Cell Host and Microbe, Professor Kanta Subbarao stressed the importance of detecting a neutralizing antibody response in recovered COVID-19 patients, and of studies of COVID-19 vaccines in animal models.
Boston Scientific Corporation today announced its exclusive sponsorship and first enrollments of the MADIT-RIT clinical trial. This new trial follows in the tradition of three previous landmark trials: MADIT, MADIT II and MADIT-CRT, each exclusively sponsored by Boston Scientific and conducted under the leadership of Principal Investigator Arthur J. Moss, M.D., Professor of Medicine at the University of Rochester.
UC Irvine neuroscientists have developed a way to stop epileptic seizures with fiber-optic light signals, heralding a novel opportunity to treat the most severe manifestations of the brain disorder.
"After a century of progress, the issues that medicine must tackle in the coming year aren't that different from the ones that faced doctors at the start of 1911, according to the observations" published Jan. 1 in a Lancet editorial, LiveScience reports (Parry, 12/30).
Patients with worsening heart failure and reduced ejection fraction who received the investigational drug vericiguat had a significantly lower rate of cardiovascular death or heart failure hospitalization compared with those receiving a placebo, based on research presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology.
› Verified 9 days ago
| Entity Name | Rush University Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093819542 PECOS PAC ID: 5496658874 Enrollment ID: O20040202000228 |
News Archive
In an article published today in Cell Host and Microbe, Professor Kanta Subbarao stressed the importance of detecting a neutralizing antibody response in recovered COVID-19 patients, and of studies of COVID-19 vaccines in animal models.
Boston Scientific Corporation today announced its exclusive sponsorship and first enrollments of the MADIT-RIT clinical trial. This new trial follows in the tradition of three previous landmark trials: MADIT, MADIT II and MADIT-CRT, each exclusively sponsored by Boston Scientific and conducted under the leadership of Principal Investigator Arthur J. Moss, M.D., Professor of Medicine at the University of Rochester.
UC Irvine neuroscientists have developed a way to stop epileptic seizures with fiber-optic light signals, heralding a novel opportunity to treat the most severe manifestations of the brain disorder.
"After a century of progress, the issues that medicine must tackle in the coming year aren't that different from the ones that faced doctors at the start of 1911, according to the observations" published Jan. 1 in a Lancet editorial, LiveScience reports (Parry, 12/30).
Patients with worsening heart failure and reduced ejection fraction who received the investigational drug vericiguat had a significantly lower rate of cardiovascular death or heart failure hospitalization compared with those receiving a placebo, based on research presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology.
› Verified 9 days ago
| Entity Name | Rush University Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457360703 PECOS PAC ID: 9234129206 Enrollment ID: O20040513000487 |
News Archive
In an article published today in Cell Host and Microbe, Professor Kanta Subbarao stressed the importance of detecting a neutralizing antibody response in recovered COVID-19 patients, and of studies of COVID-19 vaccines in animal models.
Boston Scientific Corporation today announced its exclusive sponsorship and first enrollments of the MADIT-RIT clinical trial. This new trial follows in the tradition of three previous landmark trials: MADIT, MADIT II and MADIT-CRT, each exclusively sponsored by Boston Scientific and conducted under the leadership of Principal Investigator Arthur J. Moss, M.D., Professor of Medicine at the University of Rochester.
UC Irvine neuroscientists have developed a way to stop epileptic seizures with fiber-optic light signals, heralding a novel opportunity to treat the most severe manifestations of the brain disorder.
"After a century of progress, the issues that medicine must tackle in the coming year aren't that different from the ones that faced doctors at the start of 1911, according to the observations" published Jan. 1 in a Lancet editorial, LiveScience reports (Parry, 12/30).
Patients with worsening heart failure and reduced ejection fraction who received the investigational drug vericiguat had a significantly lower rate of cardiovascular death or heart failure hospitalization compared with those receiving a placebo, based on research presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mitchell L Bressack, MD 70 W 94th Place, Crown Point, IN 46307-1710 Ph: (219) 662-8822 | Mitchell L Bressack, MD 70 W 94th Place, Crown Point, IN 46307-1710 Ph: (219) 662-8822 |
News Archive
In an article published today in Cell Host and Microbe, Professor Kanta Subbarao stressed the importance of detecting a neutralizing antibody response in recovered COVID-19 patients, and of studies of COVID-19 vaccines in animal models.
Boston Scientific Corporation today announced its exclusive sponsorship and first enrollments of the MADIT-RIT clinical trial. This new trial follows in the tradition of three previous landmark trials: MADIT, MADIT II and MADIT-CRT, each exclusively sponsored by Boston Scientific and conducted under the leadership of Principal Investigator Arthur J. Moss, M.D., Professor of Medicine at the University of Rochester.
UC Irvine neuroscientists have developed a way to stop epileptic seizures with fiber-optic light signals, heralding a novel opportunity to treat the most severe manifestations of the brain disorder.
"After a century of progress, the issues that medicine must tackle in the coming year aren't that different from the ones that faced doctors at the start of 1911, according to the observations" published Jan. 1 in a Lancet editorial, LiveScience reports (Parry, 12/30).
Patients with worsening heart failure and reduced ejection fraction who received the investigational drug vericiguat had a significantly lower rate of cardiovascular death or heart failure hospitalization compared with those receiving a placebo, based on research presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology.
› Verified 9 days ago
Melanie E. Griem, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 70 W 94th Place, Crown Point, IN 46307 Phone: 219-662-8822 Fax: 219-662-8833 | |
Ashvin Reddy Garlapati, D.O. Dermatology Medicare: Not Enrolled in Medicare Practice Location: 70 W 94th Pl, Crown Point, IN 46307 Phone: 219-662-8822 Fax: 219-662-8833 | |
Aleksandra Gabriela Florek, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 70 W 94th Pl, Crown Point, IN 46307 Phone: 219-662-8822 Fax: 219-662-8833 |